Defining the Efficacy and Safety of Phosphodiesterase Type 5 Inhibitors with Tamsulosin for the Treatment of Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia with or without Erectile Dysfunction: A Network Meta-Analysis

Table 3

The ranking of probability of different interventions was estimated by comparing the SUCRA.

Treatment	SUCRA	Pr best	Mean rank
For IPSS
T	11.2	0.0	5.4
S25+T	86.3	51.7	1.7
T5+T	71.0	25.0	2.5
T20+T	36.2	0.3	4.2
T10+T	18.9	0.0	5.1
V10+T	76.6	23.0	2.2
For
T	33.8	0.0	5.0
S25+T	80.7	7.5	2.2
T5+T	15.2	0.0	6.1
T20+T	42.7	0.0	4.4
T10+T	8.8	0.0	6.5
V10+T	70.9	1.1	2.7
S4+T	98.0	91.4	1.1
For IIEF
T	0.1	0.0	5.0
S25+T	99.9	99.6	1.0
T20+T	72.8	0.4	2.1
T10+T	35.0	0.0	3.6
V10+T	42.2	0.0	3.3
The safety outcomes of treatment comparisons
T	93.2	68.7	1.3
S25+T	63.7	4.8	2.8
T5+T	56.0	24.3	3.2
T20+T	40.0	0.0	4.0
T10+T	16.3	2.1	5.2
V10+T	30.7	0.1	4.5